Clinical Research

Before a new medical treatment can be marketed, manufacturers must show, through adequate and well-controlled clinical studies, that it is safe and effective

Participation in clinical research trials enables our physicians to gain insight and experience in many areas of cutting edge technology and pharmaceutical development. Our contribution to significant advances in the area of genitourinary research is in keeping with our goal to bring the newest and most advanced treatments and procedures to our patients.

Research trials at Urology of Indiana are conducted with the highest level of honesty and integrity. While contributions to a patient's health and well being are important, patient safety and privacy are our priorities. We enroll qualified individuals in studies including but not limited to the following categories.

  • Urinary Incontinence
  • Impotence or Erectile Dysfunction
  • Prostate Disorders
  • Benign Prostate Hyperplasia (BPH)
  • Stress Urinary Incontinence
  • Over Active Bladder
  • Complicated Urinary Tract Infection
  • Acute Urinary Retention  

We are currently conducting the following clinical trials:

Astellas 178-MA-1005 OAB

Jennifer Hargis - Friday, July 31, 2015

A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabgron in Older Adult Subjects with Overactive Bladder.

Orion (PC)

Jennifer Hargis - Friday, July 31, 2015

A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer.

Allergan 113 (OAB)

Jennifer Hargis - Friday, July 31, 2015

Complete Continence as primary Metric for Onabotulinumtoxin A Overactive Bladder Treatment Success: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study in Overactive Bladder patients with Urinary Incontinence.

Aragon/Spartan (PC)

Jennifer Hargis - Friday, July 31, 2015

Multicenter, Randomized Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 In Men With Non-Metastatic (MO) Castration-Resistant Prostate Cancer.

Mundipharama BPH

Jennifer Hargis - Friday, July 31, 2015

A Phase 2 Randomized, Double-Blind, Placebo Controlled, Study of MR901 in Patients with Moderate to Severe Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).

For more information, please call Melissa at (317) 893-1513 or Kim at 317-893-1511 or click here to e-mail our Clinical Research Department.  For more information about ongoing or upcoming studies, please click on the email link at the bottom of the page or call Melissa at 317-893-1513 or Kim at 317-893-1511.